| 包装: | 1mg |
| 市场价: | 1313元 |
Cell lines | H1299 and SKW3 cells |
Preparation Method | 6000 H1299 cells and 50000 SKW3 cells were seeded in each well of 96-well plate, treated with increasing concentrations of Sphingosine 1-phosphate (0.01-10 μM) for 24 hr and 48 hr in starvation media for MTT assay to determine the optimal concentration of Sphingosine 1-phosphate that shows maximum proliferative effect. |
Reaction Conditions | 0.001-1 μM for 24 and 48 hr |
Applications | MTT results in both cell lines showed remarkably increase in cell proliferation at a range of Sphingosine 1-phosphate concentration between 0.01 and 1 μM Sphingosine 1-phosphate after 24 hr incubation. However, there was no significant increase in the number of cells after 48 hr incubation. By increasing Sphingosine 1-phosphate concentration to above 1 μM, cell proliferation decreased compared to 1 μM concentration. |
Animal models | Rats |
Preparation Method | Acute necrotizing pancreatitis was induced by retrogradely injection of 5% sodium taurocholate of biliopancreatic duct in rats. Sphingosine-1-phosphate (100 ug/kg) or FTY720 (1 mg/kg) was administered immediately after the model induction by peritoneal injection. |
Dosage form | 100 ug/kg;i.v. |
Applications | Bronchoalveolar lavage protein concentration, total cell count, PMN percentage, proinflammatory cytokines, nuclear factor kappaB activation, lung capillary leakage, and lung myeloperoxidase were all reduced significantly in both Sphingosine 1-phosphate and FTY720 groups. The pulmonary pathological injury in both Sphingosine 1-phosphate and FTY720 groups was ameliorated obviously. Nevertheless, the serum amylase, lipase, and the pancreatic pathological damages were not decreased. |
| 产品描述 | Sphingosine 1-phosphate is a metabolic product of cell membrane sphingolipids. It is bound to extracellular chaperones, enriched in circulatory fluids and binds to G protein-coupled Sphingosine 1-phosphate receptors (Sphingosine 1-phosphateRs) used for regulating embryonic development, postnatal organ function and disease.[1] In vitro, treatment with 200 and 400 μM Sphingosine 1-phosphate in human ovarian cortical samples in dose-dependent decrease in the protein expression of cleaved caspase-3 using western blot and in the number of apoptotic follicles stained positive for cleaved caspase-3 using immunohistochemistry.[2]In vitro, with 0.1-10 μM Sphingosine 1-phosphate in a concentration-dependent manner evoked action potential (AP) generation by single fibre electrophysiological recordings.[3]In addition, using Ca2+ imaging experiments, Sphingosine 1-phosphate at 1 μM can elicit a transient increase in intracellular Ca2+ in astrocytes, followed by sustained elevation.[4] In vivo, superfusion of 0.001-10 μM Sphingosine 1-phosphate evoked in concentration-dependent manner vasoconstriction in preglomerular microvessels, predominantly afferent arterioles.[5]In vivo experiment it shown that injection 10 mg/kg sphingosine 1-phosphate intravenously in mice caused immediate rigor and death.[6]In male beagles, treatment with 85 ug/kg Sphingosine 1-phosphate intravenously decreased the formation of Q(s)/Q(t) (32%), and both the presence of protein (72%) and neutrophils (95%) in BAL fluid compared with vehicle controls. However, Sphingosine 1-phosphate increased the LPS-induced systemic production of three inflammatory cytokines, TNF-alpha (6-fold), KC (1.2-fold), and IL-6 (3-fold), without resulting in end-organ dysfunction.[7] References: |
m.cnreagent.com